Xevinapant Show Survival Rate Nearly Doubled in with Unresected LA SCCHN
07 Sep 2022 //
BUSINESSWIRE
Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients
07 Sep 2022 //
BUSINESSWIRE
Debiopharm Launches TrilynX - A Large-Scale Ph III Trial to Xevinapant
01 Oct 2020 //
PRNEWSWIRE